Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28833528 | 0.98 | ALDH1A1 (0.59) | ALDH1A1RAB9ANPC1TP53POLB | |
| SCHEMBL10074441 | 0.91 | HDAC1 (0.62) | ALDH1A1POLBSMN1; SMN2GAATHRB | |
| SCHEMBL5310198 | 0.87 | HDAC6 (0.54) | ALDH1A1POLBSMN1; SMN2GAATHRB | |
| SCHEMBL28818566 | 0.86 | ALDH1A1 (0.61) | ALDH1A1RAB9ANPC1TP53POLB | |
| SCHEMBL65179 | 0.86 | HDAC6 (0.69) | ALDH1A1RAB9ANPC1TP53POLB | |
| SCHEMBL16356429 | 0.86 | HDAC6 (0.69) | ALDH1A1RAB9ANPC1TP53POLB | |
| SCHEMBL27519383 | 0.86 | HDAC4 (0.71) | ALDH1A1NPC1POLBSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL3272318 | 0.85 | HDAC6 (0.68) | ALDH1A1POLBSMN1; SMN2GAATHRB | |
| SCHEMBL2776747 | 0.85 | ALDH1A1 (0.59) | ALDH1A1RAB9ANPC1TP53POLB | |
| Hydrochloric Acid SCHEMBL846616 | 0.85 | HDAC6 (0.68) | ALDH1A1POLBSMN1; SMN2GAATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2166860-B1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA CELLULAR THERAPIES INC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160075683-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | LI PENG (US) | 2016-03-17 | — | — | US | disclosed |
| US-9062023-B2 | Heterocycle compounds and uses thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| EP-1840122-B1 | AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF | SUN PIAOYANG (CN) | 2013-08-28 | — | — | EP | disclosed |
| US-8183242-B2 | Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof | Sun, Piaoyang (CN) | 2012-05-22 | — | — | US | disclosed |
| US-20100184778-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. | 2010-07-22 | — | — | US | disclosed |
| EP-2166860-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | Intra-Cellular Therapies, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| CN-101198604-A | NPY antagonists, their preparation and use | CEREP (FR) | 2008-06-11 | — | — | CN | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| CN-101056632-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-10-17 | — | — | CN | disclosed |
| EP-1840122-A1 | AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF | Sun, Piaoyang (CN) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
| CN-1636980-A | Dipeptide nitrile cathepsin K inhibitors | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
| CN-1183122-C | Dipeptide nitrile cathepsin K inhibitors | ��˹��ŵ�� | 2005-01-05 | — | — | CN | disclosed |
| CN-1398260-A | Dipeptide nitrile cathepsin K inhibitors | NOVARTIS AG (CH) | 2003-02-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075683-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | APP, BACE1, PYGB | ALDH1A1 2344/4885RAB9A 2114/4885NPC1 667/4885 |
| US-20100184778-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | APP, PYGB, BACE1 | ALDH1A1 2686/4885RAB9A 2099/4885NPC1 759/4885 |
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | ALDH1A1 4542/4885RAB9A 2492/4885NPC1 2338/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | ALDH1A1 3678/4885RAB9A 1324/4885NPC1 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.